Brighton Jones LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 261.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 948 shares of the biopharmaceutical company’s stock after purchasing an additional 686 shares during the quarter. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. International Assets Investment Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. Icon Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. State Street Corp grew its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Regeneron Pharmaceuticals by 40.2% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after purchasing an additional 55,828 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ:REGN opened at $675.79 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 1.59 and a beta of 0.10. The stock’s 50-day moving average price is $727.19 and its two-hundred day moving average price is $937.77. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.